Key result
Radiotherapy is linked to improved overall survival in synovial sarcoma, yielding an ~86% three-year survival.
Why the study?
Synovial sarcoma is a rare soft tissue sarcoma, and available data regarding patient survival outcomes remain limited.
Observational (n=237)
No
In patients with synovial sarcoma, survival outcomes significantly decrease with age and tumor size, while radiotherapy serves as an independent positive prognostic factor.
Answers are grounded in this paper and cite their sources.
Radiotherapy may improve survival in synovial sarcoma; observational data leave open need for prospective validation.
Background. Synovial sarcoma (SS) is a rare soft tissue sarcoma. Available data regarding survival outcomes of patients with SS still remains limited. In this study, a single center retrospective analysis was performed to investigate the clinical characteristics, pathology and survival outcomes in patients with SS in China. Methods. Patient data were systematically reviewed at the National Cancer Center from January 2015 to December 2020. The general information and treatment condition of patients were collected. Overall survival (OS) was evaluated using the Kaplan-Meier and Cox regression method. Results. A total of 237 consecutive patients were included in this study (follow-up cut-off date: December, 2020). The median age of patients involved was 35 years (ranging from 5 to 83 years) and the mean tumor diameter was 5.3 cm (ranging from .2 to 26.0 cm). The main findings of the immunohistochemical staining analyses were EMA (111/156) (71%), keratin 7 (32/64) (50.0%), keratin 8/18 (12/20) (60%), keratin 19 (42/70) (60%), S-100 (18/160) (11%), BCL2 (128/134) (96%), CD99 (137/148) (93%) and TLE1 (23/26) (88%). It was found that 109 patients (66%) were presented with monophasic subtype and 55 (34%) with biphasic subtype. A total of 137 patients were tested by FISH method and 119 patients (87%) demonstrated SS18 rearrangement, whereas 18 patients (13%) did not show SS18 rearrangement. Generally, it was found that the 3-year OS rate was 86% and the 3-year DFS was 55%. Results of univariate analysis revealed that age, tumor size, tumor site, radiotherapy and targeted therapy were significantly correlated with the overall survival ( P < .05). Further, multivariate Cox regression analysis revealed that age, tumor size and radiotherapy were significantly associated with OS ( P < .05). Conclusions. In conclusion, this study shows that the outcomes of patients with SS significantly decrease with age and tumor size. It was evident that radiotherapy is an independent and positive prognostic factor for patients with SS. In addition, it was shown that the prognosis of SS varies with tumor location. For instance, primary tumors in lower extremities have a higher prognosis, whereas tumors located in thorax have a lower prognosis.
No takes yet. Share an insight, caveat, or question.
Cheng et al. (2021) conducted an observational in Synovial sarcoma (n=237). Radiotherapy was evaluated on Overall survival (p=< .05). In patients with synovial sarcoma, radiotherapy was an independent positive prognostic factor for overall survival, with an overall 3-year survival rate of 86%.
Synapse has enriched 10 related papers. Consider them for comparative context: